{"filings":[{"id":2078879,"accession_number":"0001649094-26-000041","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2026-08-05T20:07:51+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte Q2 net loss $284M; VAX-31 OPUS-1 topline data expected Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $284.3M in Q2 2026 vs $166.6M in Q2 2025; R&D expenses rose to $267.9M.","Cash, equivalents and investments $2.5B as of June 30, 2026, up from $2.44B at year-end 2025.","VAX-31 adult Phase 3 OPUS-1 noninferiority trial fully enrolled; topline data due Q4 2026.","VAX-31 infant Phase 2 dose-finding study data expected by end of H1 2027.","Phase 1 study of VAX-A1 (Group A Strep) initiated; topline data expected H2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1664276,"accession_number":"0001649094-26-000030","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2026-07-15T20:05:37+00:00","items":["5.02"],"status":"ready","headline":"Vaxcyte director Heath Lukatch retires; John Markels appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Heath Lukatch retired from Vaxcyte board effective July 16, 2026; no disagreement with company.","John Markels appointed as Class II director, term expiring at 2028 annual meeting.","Markels will serve on Audit and Compensation committees; qualifies as independent under Nasdaq rules.","Markels receives standard non-employee director compensation; annual equity grant currently $430,000.","No transactions or arrangements between Markels and company requiring disclosure under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1222196,"accession_number":"0001649094-26-000026","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2026-06-23T20:09:09+00:00","items":["5.02"],"status":"ready","headline":"Vaxcyte director Jacks Lee retires; Moncef Slaoui appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jacks Lee retired from the Board effective June 17, 2026; no disagreement with the company.","Lee entered a consulting agreement for global strategic supply and manufacturing operations.","Moncef Slaoui appointed as Class II director effective June 17, 2026; term expires at 2028 annual meeting.","Slaoui deemed independent under Nasdaq rules; will receive standard non-employee director compensation with annual equity grant valued at $430,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1083997,"accession_number":"0001649094-26-000021","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2026-06-16T20:12:10+00:00","items":["5.07"],"status":"ready","headline":"Vaxcyte shareholders re-elect all three Class III directors, ratify Deloitte, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three Class III directors re-elected: Brandicourt (116.4M for), Gilbert (114.7M for), Pickering (132.1M for); 4.4M broker non-votes.","Ratification of Deloitte as auditor for FY2026 passed with 137.2M for, 137,589 against, 862 abstain.","Non-binding advisory vote on named executive officer compensation approved with 130.0M for, 2.8M against, 247,195 abstain, 4.4M broker non-votes.","All proposals passed as recommended by the board; no material strategic or financial changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94385,"accession_number":"0001649094-26-000015","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte Q1 net loss $320.6M; OPUS Phase 3 enrollment completed; topline data Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $2.74B as of Mar 31, up from $2.44B Dec 31; includes $601.8M from Feb 2026 equity offering.","Net loss $320.6M for Q1 2026 vs $140.7M in Q1 2025; R&D expenses doubled to $312.8M.","All three VAX-31 adult Phase 3 trials (OPUS-1, OPUS-2, OPUS-3) fully enrolled with 6,191 adults dosed.","Topline OPUS-1 data expected Q4 2026; OPUS-2 and OPUS-3 data expected H1 2027.","VAX-31 infant Phase 2 fully enrolled (900 infants); topline data by end of H1 2027; VAX-A1 Phase 1 start mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106726,"accession_number":"0001649094-26-000005","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte reports 2025 net loss of $766.6M; cash $2.44B plus $600M from Feb equity offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 net loss $766.6M vs $463.9M in 2024; R&D expenses $794.3M (up 67% YoY).","Cash, equivalents, investments $2.44B at Dec 31, 2025; $632.5M gross from Feb 2026 public offering.","VAX-31 adult Phase 3 program (OPUS-1/2/3) underway; topline OPUS-1 data expected Q4 2026, OPUS-2/3 in H1 2027.","VAX-31 infant Phase 2 dose-finding study (900 infants) fully enrolled; data from series and booster expected by H1 2027.","Plan to initiate Phase 1 study for Group A Strep vaccine candidate VAX-A1 in 2026; dedicated Lonza facility completed."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106725,"accession_number":"0001193125-26-067546","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxcyte enters $500M at-the-market equity offering; terminates prior $270.3M ATM with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales agreement with Leerink Partners for up to $500M in common stock via at-the-market offerings.","Placement agent receives up to 3.00% compensation on gross proceeds from sales.","Terminated prior sales agreement with Jefferies under which $270.3M had been sold.","Company not obligated to sell any shares; no assurance of any sales under new agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106724,"accession_number":"0001193125-26-033578","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxcyte raises $600.2M in public offering of 12.65M shares at $50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 11M shares at $50.00 public price; underwriter option for 1.65M shares exercised.","Net proceeds of approximately $600.2M after underwriting discounts and expenses.","Underwriters purchased shares at $47.50 each; offering closed on February 2, 2026.","Proceeds will support general corporate purposes, including pipeline development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123042,"accession_number":"0001649094-25-000116","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Vaxcyte boosts severance multipliers for CEO Pickering and three other execs effective Dec 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Pickering: base salary severance multiplier for Qualifying Termination increases to 1.5x (from 1.0x); CIC termination to 2.0x (from 1.5x).","CFO Guggenhime, COO Wassil, CTOO Dhaliwal: non-CIC multiplier rises to 1.0x (from 0.75x/0.5x); CIC to 1.5x (from 1.0x/0.75x).","COBRA severance multipliers increased proportionally across all four executives.","Changes effective Dec 31, 2025, approved by Compensation Committee to align with peer group levels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123041,"accession_number":"0001649094-25-000112","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte Q3 net loss $212.8M; cash $2.67B; VAX-31 adult pivotal study start Dec 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $212.8M for Q3 2025 vs $103.1M in Q3 2024; R&D expenses $209.9M, up from $116.9M.","Cash, cash equivalents and investments $2.67B as of Sept 30, 2025, expected to fund operations into mid-2028.","Final VAX-24 infant Phase 2 data show robust dose-dependent immune responses, validating higher VAX-31 doses.","VAX-31 adult pivotal non-inferiority study to start Dec 2025; topline data expected in 2026.","Up to $1B fill-finish agreement with Thermo Fisher in North Carolina for long-term U.S. commercial supply."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139741,"accession_number":"0001649094-25-000102","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Vaxcyte signs 15-year manufacturing deal with Thermo Fisher's Patheon","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement covers formulation, fill, finish, testing at Patheon's Greenville, NC facility.","Binding minimum purchase commitments; termination fee in mid-eight-figures for convenience.","Initial 15-year term with auto-renewal; includes tech transfer and capex reimbursement.","Customary termination rights for cause, regulatory breach, or insolvency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139740,"accession_number":"0001649094-25-000096","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte Q2 net loss $166.6M, cash $2.83B; VAX-31 Phase 3 on track for Q4 start","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $166.6M for Q2 2025 vs $128.7M a year ago; R&D expenses $194.2M, up from $131.5M.","Cash, cash equivalents and investments $2.83B as of June 30, 2025; cash runway extended to mid-2028.","VAX-31 adult pivotal non-inferiority study to begin Q4 2025 with topline data expected in 2026.","VAX-31 infant Phase 2 modified: new optimized dose arm added, low dose arm discontinued; data by H1 2027.","Early pipeline streamlined: paused VAX-A1 and VAX-GI, discontinued VAX-PG due to insufficient efficacy."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157298,"accession_number":"0001649094-25-000084","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vaxcyte shareholders re-elect all three Class II directors and approve officer exculpation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["John Furey reelected with 120.7M For vs 0.4M Withheld; Jacks Lee 107.3M For vs 13.8M Withheld.","Heath Lukatch, Ph.D. reelected with 99.2M For vs 21.9M Withheld.","Deloitte & Touche ratified as auditor for FY2025 with 124.8M For, 0.2M Against.","Advisory say-on-pay passed with 77.1M For, 44.0M Against, 4.0M broker non-votes.","Amendment to certificate for officer exculpation approved with 112.3M For, 8.8M Against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157297,"accession_number":"0001649094-25-000073","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte Q1 net loss $140.7M; VAX-24 infant data positive, VAX-31 Phase 3 set for mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $140.7M vs $95.0M YoY; cash, equivalents & investments $2.95B at March 31, 2025.","VAX-24 infant Phase 2 met non-inferiority criteria for 20 of 24 serotypes; robust OPA responses.","VAX-31 infant Phase 2 advanced to second stage; adult Phase 3 non-inferiority study to start mid-2025.","New third-generation PCV candidate VAX-XL announced to further expand serotype coverage.","Dr. Olivier Brandicourt (ex-Sanofi CEO) appointed to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157296,"accession_number":"0001649094-25-000057","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vaxcyte appoints Dr. Olivier Brandicourt to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective May 1, 2025 as a Class III director with term expiring at 2026 annual meeting.","Board determined Dr. Brandicourt qualifies as independent under Nasdaq rules.","Receives initial equity award of $800,000 in nonstatutory stock options vesting over 36 months.","Annual cash retainer of $50,000 and annual equity award of $450,000 (75% option, 25% RSU).","Standard indemnification agreement entered; no reportable transactions per Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175685,"accession_number":"0001193125-25-067901","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vaxcyte reports positive VAX-24 infant Phase 2 topline; selects mid dose; announces VAX-XL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VAX-24 well-tolerated; safety similar to Prevnar 20; no related serious adverse events.","Mid dose (2.2mcg) met non-inferiority criteria on seroconversion for 20 of 24 serotypes; dose-dependent responses with little carrier suppression.","Four VAX-24-unique serotypes met all target criteria at all doses evaluated.","Company selects mid dose for optimized formulation; plans infant Phase 3 with VAX-24 or VAX-31 pending VAX-31 data (mid-2026).","Announces VAX-XL, third-generation PCV candidate designed to provide broadest coverage PCV in development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175684,"accession_number":"0001649094-25-000027","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte reports Q4 2024 net loss of $137.1M; cash $3.13B; VAX-31 Phase 3 on track for mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024: $137.1M; full year 2024: $463.9M vs $402.3M in 2023.","Cash, cash equivalents and investments: $3.13B at Dec 31, 2024, up from $1.24B a year ago.","R&D expenses $133.6M in Q4; $476.6M for full year on increased PCV program activities.","VAX-31 adult Phase 3 pivotal study expected to start by mid-2025 with topline data in 2026.","VAX-24 infant Phase 2 primary immunization topline data expected by end of Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192630,"accession_number":"0001193125-24-263406","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["1.01","8.01"],"status":"ready","headline":"Vaxcyte amends HQ lease to 258,581 RSF, subleases 16,731 SF to Iovance Biotherapeutics","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended lease expands premises from ~113k to 258,581 RSF across floors 1-6, phased move-ins Feb 2025 through June 2026.","Initial base rent $5.941-$6.026/RSF/month for existing premises; $6.00/RSF for additional; 8-month abatement, 3% annual escalations.","Lease term 120 months from first additional premises commencement, with two 5-year renewal options.","Subleased 16,731 RSF of Suite 100A to Iovance Biotherapeutics for 2 years at $5.95/RSF, rising to $6.1285/RSF after year one.","Security deposit of ~$1.09M in letters of credit carried over from prior leases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192629,"accession_number":"0001649094-24-000096","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte reports Q3 net loss $103M; cash $3.27B after $1.4B follow-on","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $103.1M for Q3 2024 vs $92.7M in Q3 2023.","Cash, equivalents and investments $3,273M as of Sep 30, 2024, up from $1,243M at Dec 31, 2023.","VAX-31 Phase 1/2 topline positive: met non-inferiority vs PCV20 for all 20 shared serotypes at middle/high doses.","VAX-31 selected for Phase 3 adult program; pivotal non-inferiority study initiation expected by mid-2025.","VAX-24 infant Phase 2 primary series topline data expected by end of Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209079,"accession_number":"0001193125-24-214711","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxcyte raises $1.42B in underwritten public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 10,194,175 shares at $103.00/share and pre-funded warrants to purchase 2,427,184 shares at $102.999/warrant.","Underwriters' 30-day option for additional 1,893,203 shares exercised in full.","Net proceeds expected to be approximately $1.42 billion after discounts and expenses.","Closing expected on or about September 6, 2024, subject to customary conditions.","Offering made under effective shelf registration statement (Form S-3)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209078,"accession_number":"0001193125-24-211572","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vaxcyte reports positive Phase 1/2 data for VAX-31; all serotypes meet immunogenicity criteria","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VAX-31 showed robust OPA responses for all 31 serotypes at all doses; safety profile similar to Prevnar20.","At high and middle doses, VAX-31 met or exceeded non-inferiority criteria for all 20 serotypes common with PCV20.","For 11 unique serotypes, all three doses met superiority criteria.","Company selects VAX-31 for adult Phase 3; plans to initiate pivotal study by mid-2025 with topline data in 2026.","Also plans VAX-31 infant Phase 2 study in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209077,"accession_number":"0001649094-24-000051","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte Q2 net loss $128.7M; cash $1.85B; VAX-31 adult data due Sept 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $128.7M for Q2 2024 vs $68.3M in Q2 2023; R&D expenses $131.5M, up from $72.7M.","Cash, cash equivalents and investments $1,851.9M as of June 30, 2024, up from $1,242.9M at Dec 31, 2023.","VAX-31 adult Phase 1/2 topline safety and immunogenicity data expected in September 2024; will then select VAX-24 or VAX-31 for Phase 3.","VAX-24 infant Phase 2 topline from primary series due by end of Q1 2025; booster data by end of 2025.","Appointed John Furey to Board; received $9.5M NIAID grant for Chlamydia vaccine program."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209076,"accession_number":"0001193125-24-174317","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vaxcyte appoints John P. Furey to Board of Directors, effective July 2, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John P. Furey appointed as Class II director; term expires at 2025 annual meeting.","Furey received initial stock option valued at $800,000 vested over 36 months; also joins Compensation Committee.","Annual equity awards of $450,000 (75% option, 25% RSU) and cash retainers of $50,000 board / $7,500 committee.","Indemnification agreement executed; Furey qualifies as independent director under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226924,"accession_number":"0001193125-24-158355","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vaxcyte shareholders re-elect Class I directors, ratify Deloitte as auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annie Drapeau re-elected with 82,886,170 votes for; Teri Loxam with 96,840,846; Carlos Paya with 96,685,408.","Ratification of Deloitte & Touche as auditor for FY 2024: 103,807,993 for, 14,745 against, 24,027 abstain.","Non-binding advisory vote on executive compensation approved: 91,072,269 for, 7,934,248 against, 23,235 abstain.","Three Class I directors to serve until 2027 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226923,"accession_number":"0001628280-24-021665","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte reports Q1 net loss $95M, cash $1.9B; VAX-31/24 enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments $1.9B at March 31, 2024, up from $1.24B at Dec 31, 2023, including $816.5M net from Feb offering.","Net loss $95.0M vs $60.5M in Q1 2023; R&D expenses rose to $94.6M from $58.1M.","VAX-31 adult Ph1/2 enrollment completed; topline safety/immunogenicity data expected Q3 2024.","VAX-24 infant Ph2 enrollment completed; topline data from primary series expected by end Q1 2025.","Plan to advance either VAX-24 or VAX-31 to adult Ph3 after VAX-31 data; if VAX-24, Ph3 start H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245871,"accession_number":"0000950170-24-021081","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte FY23 net loss $402M; VAX-31 adult Phase 1/2 topline data Q3 2024; cash $1.24B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $402.3M for FY2023 (vs $223.5M in FY2022); cash, equivalents & investments $1.24B as of Dec 31, 2023.","VAX-31 adult Phase 1/2 study enrollment complete; topline safety, tolerability & immunogenicity data expected Q3 2024.","VAX-24 adult program Phase 3-ready following End-of-Phase 2 FDA meeting; either VAX-24 or VAX-31 to advance after VAX-31 readout.","VAX-24 infant Phase 2 enrollment nearing completion; topline data from primary series by end Q1 2025, booster by end 2025.","R&D expenses $332.3M for FY2023, up 96% YoY due to manufacturing scale-up for PCV programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245870,"accession_number":"0001193125-24-021084","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxcyte Raises $816.5 Million in Public Offering of Common Stock and Pre-Funded Warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriting agreement with BofA, Jefferies, Leerink, Evercore for 10,937,500 shares at $64.00 per share and 781,250 pre-funded warrants at $63.999 per warrant.","Pre-funded warrants have an exercise price of $0.001 per share and are exercisable until fully exercised subject to an ownership limitation.","Underwriters exercised option in full for an additional 1,757,812 shares, bringing total shares offered to 12,695,312.","Net proceeds expected to be approximately $816.5 million after underwriting discounts and expenses.","Closing expected on or about February 2, 2024, under effective registration statement on Form S-3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263334,"accession_number":"0001193125-23-283769","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vaxcyte appoints Jacks Lee to Board of Directors, effective Nov 27, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jacks Lee appointed as Class II director, term expires at 2025 annual meeting.","Lee appointed to Audit Committee; Board determined independent under Nasdaq rules.","Initial grant of 30,000 stock options, vesting 1/3 at one year and monthly over 36 months.","Annual grants: option for 15,000 shares and 2,500 RSUs, with accelerated vesting on change of control.","Annual cash retainers: $40,000 for Board service, plus $10,000 for Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263333,"accession_number":"0001193125-23-283354","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Vaxcyte exercises option for manufacturing rights; pays $50M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exercised option on Nov 21, 2023; paid $50M cash; owes $25M within 6 months.","Manufacturing Rights Agreement grants exclusive, perpetual, royalty-free license to manufacture Extract for vaccines.","Up to $60M in additional milestone payments upon regulatory milestones.","Amendments to License and Supply Agreements to ensure consistency with new agreement.","Option allows Vaxcyte to directly source Extract from CMOs and independently develop improvements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263332,"accession_number":"0000950170-23-059386","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte Q3 net loss $92.7M; FDA clears VAX-31 IND; VAX-24 Phase 3 agreed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $92.7M vs $57.9M YoY; cash $1.43B (up from $957.9M Dec 2022).","Completed End-of-Phase 2 FDA meeting for VAX-24 adult Phase 3; topline data expected 2025.","FDA cleared VAX-31 adult IND; Phase 1/2 starts Q4 2023, topline data H2 2024.","Expanded Lonza collaboration for commercial manufacturing of VAX-24 and VAX-31.","VAX-24 infant Phase 2 advanced to Stage 2 with comparator Prevnar 20."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263331,"accession_number":"0001193125-23-256533","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2023-10-16T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Vaxcyte subsidiary signs commercial manufacturing deal with Lonza for pneumococcal vaccine","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lonza will build a dedicated suite in Visp, Switzerland to manufacture drug substance for Vaxcyte's pneumococcal conjugate vaccine franchise.","Vaxcyte GmbH pays CHF 27M repurposing fee within 30 days, credited over 10 years from commercial production start.","Agreement term through Dec 31, 2038, renewable for three 5-year periods; termination penalty up to CHF 70M under certain conditions.","Vaxcyte retains right to use alternate manufacturers; receives perpetual, royalty-free license to Lonza's IP for the Products.","Pre-commercial service fees and capital expenditure contributions commence before suite certification for commercial operation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263330,"accession_number":"0001193125-23-250816","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2023-10-04T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Vaxcyte and Sutro finalize Form Definitive Agreement; amend license terms","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["On Sep 28, 2023, Vaxcyte and Sutro mutually agreed on the Form Definitive Agreement to become effective if Vaxcyte exercises the option to source extract.","Concurrently, the companies entered the 2023 Amendment to the Sutro License Agreement, modifying royalty reductions, IP prosecution, and royalty payment reporting.","The previously agreed $5.0M cash payment to Sutro remains due within five business days after mutual agreement on the Form Definitive Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280541,"accession_number":"0001193125-23-230628","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Vaxcyte expands HQ by assuming 36,593 sq ft lease at 825 Industrial Road, San Carlos","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Assumed lease from Codexis for ~36,593 rentable sq ft at 825 Industrial Road, San Carlos.","Lease term expires November 30, 2031; base rent starts at $5.85/sq ft/month with 3% annual increases.","Three-month rent abatement after effective date (expected ~October 1, 2023).","Company to provide $220,656 letter of credit as security deposit.","This expansion supplements existing 77,734 sq ft Vaxcyte headquarters lease at the same building."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280540,"accession_number":"0000950170-23-039777","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte reports Q2 net loss $68.3M, cash $1.44B, VAX-24 infant Phase 2 advanced to Stage 2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $1.44B as of June 30, includes $545M net from April public offering.","Net loss $68.3M for Q2 2023 vs $48.5M in Q2 2022; R&D expenses $72.7M.","VAX-24 infant Phase 2 advanced to final stage; topline primary data expected by 2025.","VAX-24 adult Phase 2 positive; Phase 3 topline data expected 2025; VAX-31 IND clearance expected Q4 2023.","Board member Michael Kamarck passed away in July 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299124,"accession_number":"0001193125-23-167882","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vaxcyte stockholders re-elect three Class III directors, ratify Deloitte, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III directors Halley Gilbert, Michael Kamarck, and Grant Pickering re-elected with over 61M votes each.","Ratification of Deloitte & Touche as independent auditor for FY2023 approved with 74.9M for, 3,583 against.","Non-binding advisory vote on named executive officer compensation approved with 62.9M for, 7.2M against.","Broker non-votes were 4,802,816 on director election and say-on-pay matters.","All three proposals passed as recommended by the board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299123,"accession_number":"0000950170-23-018818","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte reports Q1 net loss $60.5M; VAX-24 Phase 2 meets endpoints in adults 65+","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $60.5M in Q1 2023 vs $39.0M in Q1 2022; R&D expenses $58.1M, up from $31.7M.","Cash, cash equivalents and investments $949.9M as of March 31, 2023, excluding $545.1M net proceeds from recent public offering.","Positive Phase 2 data for VAX-24 in adults 65+: at 2.2mcg dose, met OPA non-inferiority for 18/20 common serotypes vs PCV20 and superiority for all 4 unique serotypes.","Dosed first participants in VAX-24 infant Phase 2 study; topline data expected by 2025.","Completed $575M follow-on public offering in April 2023; VAX-31 IND submission expected H2 2023, Phase 1/2 data in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299122,"accession_number":"0001193125-23-106984","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2023-04-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxcyte raises $544.5M net via public offering of stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 11.2M shares at $41.00 and pre-funded warrants for 1M shares at $40.999 each.","Underwriters exercised option to purchase additional 1.83M shares, increasing total proceeds.","Net proceeds expected to be $544.5M after underwriting discounts and expenses.","Closing expected April 21, 2023, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299121,"accession_number":"0001193125-23-102874","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxcyte reports positive Phase 2 data for VAX-24 in adults 65+; met key immunogenicity criteria vs Prevnar 20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VAX-24 2.2mcg dose met OPA non-inferiority for 18 of 20 serotypes common with Prevnar 20 and superiority for all four unique serotypes.","Robust immune responses across all 24 serotypes at all doses in adults 65+, confirming prior Phase 2 results in adults 50-64.","Full six-month safety data from both adult studies showed VAX-24 safety and tolerability similar to PCV20 with no related serious adverse events.","Prespecified pooled analyses (age 50+ and 60+) showed VAX-24 2.2mcg met OPA non-inferiority for all 20 common serotypes and superiority for four unique.","Company plans End-of-Phase 2 meeting with FDA in H2 2023; topline Phase 3 data in adults expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319299,"accession_number":"0001193125-23-061401","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Vaxcyte enters into Master Services Agreement with Lonza for manufacturing of VAX-24 and VAX-31 components","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement effective March 1, 2023, for manufacturing process development and production of polysaccharide antigens, eCRM carrier, and conjugated drug substances.","Vaxcyte owns IP directly derived from its materials or improvements to its background IP; Lonza owns generally applicable IP and improvements to its background IP.","Lonza grants Vaxcyte a non-exclusive, worldwide, fully paid-up, transferable license under new general application IP for products manufactured under the agreement.","Initial term of five years with automatic renewal for two years unless either party gives two years' non-renewal notice before the fifth anniversary.","Either party may terminate for material breach, insolvency, extended force majeure, or scientific/technical impossibility; Vaxcyte may also terminate on a project-by-project basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319298,"accession_number":"0001193125-23-050965","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxcyte increases ATM equity offering capacity from $150M to $400M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to Sales Agreement with Jefferies raises aggregate offering amount to $400M.","As of Feb 27, 2023, ~$137.8M had been sold under the prior $150M ATM program.","Material terms unchanged; sales made via at-the-market offerings on Nasdaq.","Shares registered under existing shelf registration statement; no obligation to sell."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319297,"accession_number":"0000950170-23-004639","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte reports Q4 2022 net loss of $78.1M; cash $957.9M; VAX-24 infant IND cleared","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $78.1M for Q4 2022 and $223.5M for full year 2022; R&D expenses $51.6M and $169.5M respectively.","Cash, cash equivalents and investments $957.9M as of Dec 31, 2022, up from $273.1M a year ago.","FDA cleared VAX-24 infant IND; Phase 2 infant study to start Q2 2023; Breakthrough Therapy designation for adults.","Positive Phase 1/2 data for VAX-24 in adults 18-64; Phase 2 study in adults 65+ enrollment completed; topline data expected Q2 2023.","Raised ~$805M in gross proceeds from two follow-on equity offerings in 2022; VAX-31 adult IND expected H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337515,"accession_number":"0001193125-22-309137","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2022-12-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Vaxcyte in option deal with Sutro for cell-free extract; $22.5M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront consideration of $22.5M: $10M cash, $7.5M stock (due within 5-7 days), $5M after Form Definitive Agreement.","Option exercise price of $75M cash in two installments plus up to $60M in regulatory milestone payments.","Vaxcyte gains right to directly source cell-free extract from CMOs and option for exclusive internal manufacture/improvements.","Option period is five years, subject to acceleration upon change of control of Vaxcyte.","Agreement supports Vaxcyte's vaccine pipeline by securing supply and development rights for extract."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337514,"accession_number":"0001193125-22-302736","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vaxcyte appoints Elvia Cowan as principal accounting officer effective Jan 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elvia Cowan, 50, currently SVP Finance since July 2022, appointed principal accounting officer.","Previously VP Controller at 23andMe (Oct 2018 - Mar 2022) and CFO at Ruby Ribbon.","Andrew Guggenhime remains President and CFO, stepping down as principal accounting officer.","Cowan is a CPA in California and holds a B.A. in Business Administration from Mount Saint Mary's University."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337513,"accession_number":"0000950170-22-022628","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte reports positive VAX-24 Phase 1/2 data; Q3 net loss $57.9M, cash $366.2M plus $650.7M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $57.9M (vs $26.6M YoY); R&D $47.7M (up from $20.4M) on Phase 3/IND activities.","Cash $366.2M at Sep 30, plus ~$650.7M net from Oct follow-on offering.","VAX-24 Phase 1/2 met endpoints; at 2.2mcg dose, non-inferiority for all 20 PCV20 serotypes, 16 higher, 4 superior.","Expect VAX-24 Phase 2 data in 65+ in H1 2023; infant IND in H1 2023; VAX-XP IND in H2 2023.","Appointed Mark Wiggins as CBO and Jakub Simon as CMO."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337512,"accession_number":"0001193125-22-270039","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxcyte prices $650.7M underwritten public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Selling 15M shares at $32.00/share and pre-funded warrants for 3.75M shares at $31.999 each.","Underwriters exercised option to purchase additional 2,812,500 shares; net proceeds expected ~$650.7M.","Closing expected October 28, 2022, subject to customary closing conditions.","Underwriting agreement filed as Exhibit 1.1; pre-funded warrant form filed as Exhibit 4.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337511,"accession_number":"0001193125-22-267147","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2022-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxcyte VAX-24 Phase 1/2 meets all endpoints; 2.2mcg dose advances to Phase 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VAX-24 safety profile similar to Prevnar 20 at all doses; no related SAEs or chronic illnesses.","All 24 serotypes met/exceeded regulatory immunogenicity standards at 2.2mcg dose.","Of 20 serotypes common with PCV20, 16 showed higher OPA immune responses; 4 reached statistical significance.","All 4 unique serotypes (2, 9N, 17F, 20B) exceeded standard superiority criteria at all doses.","Milestones: Phase 3 adult data expected 2025; infant Phase 2 initiation in H1 2023; VAX-XP (31-valent) IND in H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354877,"accession_number":"0000950170-22-015552","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte Q2 net loss $48.5M; VAX-24 Phase 2 fully enrolled with topline data expected Oct/Nov 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments of $361.4M at June 30, 2022 (vs. $273.1M at Dec. 31, 2021).","R&D expenses $38.5M, up from $17.7M YoY due to VAX-24/VAX-XP/Phase 3 readiness activities.","Net loss $48.5M for Q2 2022 compared to $23.7M in Q2 2021.","Completed enrolment of Phase 2 portion of VAX-24 proof-of-concept study in adults 50-64 (≈800 subjects).","FDA granted Fast Track designation for VAX-24 in adults; topline results expected Oct or Nov 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372900,"accession_number":"0001193125-22-169367","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2022-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vaxcyte annual meeting: directors re-elected, say-on-pay approved, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Peter Hirth re-elected as Class II director with 44,840,461 votes for, 2,557,604 withheld.","Heath Lukatch re-elected as Class II director with 44,945,210 votes for, 2,452,855 withheld.","Say-on-pay proposal passed with 47,263,430 for, 132,867 against, 1,768 abstentions.","Future say-on-pay frequency set at one year based on 47,358,585 votes for one year.","Deloitte & Touche LLP ratified as auditor for FY2022 with 51,800,260 for, 335 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372899,"accession_number":"0000950170-22-008507","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte Q1 net loss $39M, cash $352M; VAX-24 topline results due end-2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $39.0M vs $21.2M YoY; R&D $31.7M, G&A $7.5M.","Cash, cash equivalents and investments $352.3M at March 31, 2022, including $107.6M net from public offering.","VAX-24 Phase 1/2 study dosing in both phases; topline safety, tolerability, immunogenicity results expected by year-end 2022.","Separate VAX-24 Phase 2 study in adults 65+ expected to start mid-2022; topline results expected H1 2023.","Appointed Mikhail Eydelman as SVP, General Counsel & Corporate Secretary in April 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372898,"accession_number":"0001193125-22-108155","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2022-04-18T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Vaxcyte enters manufacturing pact with Lonza for pneumococcal vaccine","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Master Services Agreement effective March 22, 2022 for clinical manufacturing of Vaxcyte's PCV.","Initial term of five years; either party may terminate for material breach, insolvency, or convenience.","Vaxcyte owns IP directly derivative of its product; Lonza owns generally applicable IP or improvements to Lonza background.","No financial terms disclosed; Lonza paid for services, pass-through costs, and a procurement fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-04-18T23:59:59+00:00|372898"}